Dihydropyrimidine Dehydrogenase Levels in Colorectal Cancer Cells Treated with a Combination of Heat Shock Protein 90 Inhibitor and Oxaliplatin or Capecitabine
Purpose: Dihydropyrimidine dehydrogenase (DPD) is the principal enzyme in the catabolism of fluoropyrimidine drugs including capecitabine. A recent report has suggested that oxaliplatin chemotherapy is associated with elevated DPD levels and chemoresistance pattern. As a newly developed chemotherape...
Saved in:
Main Authors: | Mahshid Mohammadian (Author), Shima Zeynali-Moghaddam (Author), Mohammad Hassan Khadem Ansari (Author), Yousef Rasmi (Author), Anahita Fathi Azarbayjani (Author), Fatemeh Kheradmand (Author) |
---|---|
Format: | Book |
Published: |
Tabriz University of Medical Sciences,
2019-08-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Cytotoxic effects of the newly-developed chemotherapeutic agents 17-AAG in combination with oxaliplatin and capecitabine in colorectal cancer cell lines
by: Mahshid Mohammadian, et al.
Published: (2017) -
Endogenous metabolic markers for predicting the activity of dihydropyrimidine dehydrogenase
by: Jihyun Kang, et al.
Published: (2022) -
Dihydropyrimidine dehydrogenase deficiency as a cause of fatal 5-Fluorouracil toxicity
by: Shiraz S. Fidai, et al.
Published: (2018) -
Improving single nucleotide polymorphisms genotyping accuracy for dihydropyrimidine dehydrogenase testing in pharmacogenetics
by: Annalaura Montella, et al.
Published: (2024) -
Cost-Effectiveness Analysis of Capecitabine Plus Oxaliplatin Versus Gemcitabine Plus Oxaliplatin as First-Line Therapy for Advanced Biliary Tract Cancers
by: Ruijia Chen, et al.
Published: (2022)